Thesis TrackerLoading companies…
All companies
Loading…
Thesis TrackerThesis TrackerLoading…
Recce Pharmaceuticals (ASX:RCE), a developer of synthetic anti-infectives, raised capital that NorthStar Impact Funds supported. In June 2026, NorthStar reported Recce undertook an equity raise at a 13% discount to the last closing price, noting it participated and received options as part of the offer. Recce Pharmaceuticals operates in the Healthcare sector within the Pharmaceuticals industry, and Thesis Tracker has captured 1 comment from 1 fund manager, NorthStar Impact Funds. Headquartered in Sydney, Recce Pharmaceuticals is a late-stage clinical biotech developing a new class of synthetic anti-infectives designed to address antibiotic-resistant bacteria, with lead candidate R327 in trials for diabetic foot infections and other indications, aiming to tackle the growing global threat of superbugs.
Company figures as of 15 Oct 2026. For information only.
Fund managers including NorthStar Impact Funds have invested in Recce Pharmaceuticals Ltd (ASX:RCE).
NorthStar highlights its participation in the raise, supporting Recce's late-stage development of new treatments for antibiotic-resistant infections.
The available commentary notes the raise was at a 13% discount, reflecting dilution and Recce's ongoing funding needs.
Recce Pharmaceuticals Ltd is an Australian late-stage clinical-stage biotechnology company. RCE develops and commercialises a new class of Synthetic Anti-infectives targeting antimicrobial-resistant (AMR) superbugs, a critical global health challenge. The company's pipeline addresses the growing threat of drug-resistant bacterial infections through novel antimicrobial technology, positioning RCE within the biotech and infectious disease treatment sector for investors tracking AMR-focused healthcare innovation.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.